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Abstract Analysis of the calcium-induced arachidonic acid
(AA) binding to S100A8/A9 revealed that maximal AA binding
was achieved at molar ratios of 1 mol S100A8 and 1 mol S100A9
and for values greater than 3 calciums per EF-hand. The AA
binding capacity was not induced by the binding of other bivalent
cations, such as Zn2+, Cu2+, and Mg2+, to the protein complex.
In contrast, the binding of AA was prevented by the addition of
either Zn2+ or Cu2+ in the presence of calcium, whereas Mg2+
failed to abrogate the AA binding capacity. The inhibitory effect
was not due to blocking the formation of S100A8/A9 as
demonstrated by a protein-protein interaction assay. Fluores-
cence measurements gave evidence that both Zn2+ and Cu2+
induce different conformational changes thereby affecting the
calcium-induced formation of the AA binding pocket within the
protein complex. Due to the fact that the inhibitory effect of
Zn2+ was present at physiological serum concentrations, it is
assumed that released S100A8/A9 may carry AA at inflamma-
tory lesions, but not within the blood compartment.
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1. Introduction
The two myeloid-related proteins MRP-8 (S100A8) and
MRP14 (S100A9) belong to the calcium binding proteins of
the S100 family (for review see [1^4]). These proteins form
heterodimeric complexes as well as higher order species, and
they bind polyunsaturated fatty acids in a calcium-dependent
manner [5^7]. Recently, we could demonstrate that the
S100A8/A9 protein complex represents the exclusive AA bind-
ing capacity in the neutrophilic cytosol [7]. The proteins are
expressed during myeloid di¡erentiation, and are abundant in
granulocytes and monocytes [8,9]. Elevated plasma levels of
S100A8/A9 have been found in patients su¡ering from a num-
ber of in£ammatory disorders including cystic ¢brosis, rheu-
matoid arthritis, and chronic bronchitis [10^13]. The demon-
stration that S100A8/A9 is speci¢cally secreted from human
monocytes and neutrophils upon protein kinase C activation
may indicate an extracellular role for S100A8/A9 [14,15]. The
secreted S100A8/A9 from neutrophil-like HL-60 cells has been
shown to carry the released arachidonic acid [7]. Although
there are a number of hypotheses, the exact functions of the
protein complex, especially in the extracellular milieu, remain
unknown. Stimulatory e¡ects on neutrophil adhesion have
been described for S100A9 which are reversed by S100A8
[16]. However, the study fails to identify the cell type by which
S100A9 is released independently from S100A8.
S100A8 and S100A9 are composed of two distinct helix-
loop-helix motifs (EF-hand) £anked by hydrophobic regions
at either terminus and separated by a central hinge region.
The C-terminal EF-hand has a higher a⁄nity for Ca2 and
encompasses 12 amino acids, whereas the N-terminal Ca2
binding loop is formed by 14 amino acids. The large di¡er-
ences in the Ca2 a⁄nities of both EF-hands may indicate
that they are heterobifunctional. In addition to the binding
of Ca2, human S100A9 has also been shown to bind Zn2,
and the antimicrobial activity of the secreted human S100A8/
A9 may be due to this property [17]. The zinc binding also
induces structural changes within the dimer [18]. However, the
Zn2 binding sites are apparently distinct and independent of
the two Ca2 binding domains [19]. Thus, di¡erent target
binding domains may be designed that allow interaction
with di¡erent target proteins. It has been assumed that in
some cases the biological activity of S100 proteins is regulated
by Zn2 rather than by Ca2 [20].
The present study was undertaken to analyze the e¡ects of
various bivalent cations, including Zn2, Cu2, and Mg2, on
the binding of arachidonic acid (AA) to the S100A8/A9 pro-
tein complex. We could demonstrate that these cations failed
to induce the AA binding capacity of the protein complex.
However, both zinc and copper abrogated the AA binding to
S100A8/A9 at physiological serum concentrations.
2. Materials and methods
2.1. Puri¢cation of S100A8 and S100A9 from human neutrophils
Human neutrophils were prepared from leukocyte-rich blood frac-
tions (‘bu¡y coat’) according to Mu«ller et al. [21]. S100A8 and
S100A9 were puri¢ed as described by van den Bos et al. [22] with
minor modi¢cations. Prior to use, the proteins were rechromato-
graphed by anion exchange chromatography using a UnoQ column
(Bio-Rad, Munich, Germany).
2.2. Fatty acid binding assay
Binding of [3H]AA to proteins was carried out as described earlier
[7]. For the estimation of the molar ratio of S100A8 and S100A9
within the protein complex, in a total volume of 250 Wl 1 nmol
S100A8 was incubated in bu¡er containing 20 mM Tris-HCl, pH
7.4 and 0.01% (w/v) Triton X-100 together with 1 WM [3H]AA and
di¡erent molar ratios of S100A9 as indicated for 1 h at 37‡C in the
presence of 5 mM CaCl2. For the determination of the molar ratio of
calcium ions vs. the number of EF-hands, in a total volume of 1 ml
1 nmol S100A8/A9 was incubated with increasing concentrations of
calcium as indicated and 1 WM [3H]AA. The absolute calcium con-
centrations were measured by atomic adsorption spectrophotometry.
For the analysis whether zinc induces AA binding capacity, 1 nmol
S100A8/A9 was incubated with 1 WM [3H]AA in the presence or
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absence of either calcium, zinc or magnesium at concentrations as
indicated in a total volume of 250 Wl.
2.3. Recombinant expression of S100A8 and S100A9
Both human S100A8 and S100A9 cDNAs were used as templates to
generate PCR fragments with suitable cloning ends. The PCR frag-
ments were puri¢ed and cloned into pQE32 (Qiagen, Du«sseldorf,
Germany) or pGEX2T (Pharmacia, Freiburg, Germany) following
standard protocols. Individual clones were analyzed by PCR and
SDS-PAGE. Positive clones were grown up to OD580 = 0.6 and sub-
sequently induced by 1 mM IPTG for 2 h. Cell pellets were resus-
pended in TBS, soni¢ed, frozen and stored at 320‡C. Histidine-
tagged proteins were puri¢ed using the TALON a⁄nity matrix (Clon-
tech, Heidelberg, Germany). Brie£y, cell pellets were resuspended in
TBS, 8 M urea, insoluble material was removed by centrifugation, and
the supernatant was incubated with the a⁄nity matrix. Proteins were
renatured on the column by washing with bu¡ers containing decreas-
ing urea concentrations. Finally, recombinant proteins were eluted
with TBS containing 300 mM imidazole.
Glutathione S-transferase (GST)-S100A8 and GST-S100A9 fusion
proteins were soluble in Escherichia coli, and were puri¢ed without
denaturation. Glutathione-Sepharose (Pharmacia) was added to the
cleared cell homogenate, washed and eluted with TBS containing
100 mM glutathione. Subsequently, glutathione was removed by dial-
ysis and purity of the recombinant proteins was demonstrated by
SDS-PAGE.
2.4. GST pull-down assay
GST fusion protein (10 Wg) and 10 Wg His-tagged S100A8 or
S100A9 were incubated in TBS, 1% BSA bu¡er for 1 h at room
temperature in a total volume of 100 Wl. The glutathione-Sepharose
was washed in TBS, 1% BSA three times and 25 Wl of bed volume was
added to the reaction. After 1 h incubation the glutathione-Sepharose
was washed three times with 10 volumes of washing bu¡er (0.4 M
NaCl; 20 mM Tris-HCl; 0.05% NP-40; pH 7.5). Finally, SDS sample
bu¡er was added to the glutathione-Sepharose pellet, heated to 100‡C,
and analyzed by 15% SDS-PAGE.
2.5. Fluorescence measurements
Fluorescence spectra were recorded at 20‡C with a spectro£uorom-
eter (Spex, Model FluoroMax II, Instruments SA, Munich Germany)
using protein concentrations of 5 Wg/ml (0.208 WM). The excitation
wavelength was 280 nm with a bandpass of 1 nm, and the emission
scans were recorded between 300 and 400 nm with a bandpass of 4 nm
and an integration time of 0.2 s. To avoid possible disul¢de formation
between S100A8 and S100A9, 1 mM DTT was added to the bu¡er
(20 mM Tris, pH 7.5 at 20‡C). All £uorescence spectra were bu¡er
corrected. For titration of S100A8/9 with zinc and copper, the fully
reduced complex was used in the absence of free reducing agents.
Ca2, Cu2 and/or Zn2 binding to the complex was monitored by
the change in the intrinsic Trp and Tyr £uorescence. Calcium concen-
trations ranging from 0 to 20 WM, zinc and copper concentrations
ranging from 0 to 50 WM were used for the titration. All samples
were preequilibrated overnight prior to the £uorescence measure-
ments. The absolute change of the £uorescence intensity at 342 nm
and the change in the £uorescence maximum were plotted as a func-
tion of the Ca2, Cu2 and/or Zn2 concentration as indicated.
2.6. Protein determination
Determination of protein content was performed according to
Smith et al. [23], using BSA as standard. The concentrations of the
puri¢ed proteins were accurately determined using extinction coe⁄-
cients of 0.998 for S100A8, 0.526 for S100A9 or 0.762 for S100A8/A9
at 280 nm.
3. Results and discussion
3.1. Binding of calcium to each EF-hand within S100A8/A9 is
prerequisite for AA binding
It has been assumed that the N- and C-terminal EF-hands
within the S100 proteins are heterobifunctional due to the
large di¡erences in their a⁄nity towards calcium [20]. AA
binding to S100A8/A9 has been demonstrated at calcium con-
centrations below 1 WM, the physiological range of activated
neutrophils, as well as in the extracellular milieu [7], where the
value for the calcium concentration is within the range of 1^2
mM. Therefore, we performed fatty acid binding assays with
S100A8/A9 at a molar ratio of 1:1 in the presence of increas-
ing calcium concentrations (Fig. 1). We found that the AA
binding capacity of the protein complex increased with the
number of calcium ions per EF-hand. Maximal AA binding
was achieved for values greater than 3 calciums per EF-hand
within the S100A8/A9 molecule. Excess calcium did not a¡ect
AA binding capacity of the protein complex. These results
revealed that binding of one calcium ion to each of the four
EF-hands present in the heterodimer is a prerequisite for the
induction of the AA binding capacity.
3.2. S100A8/A9 complex consist of equal mols S100A8 and
S100A9
The calculation of calcium ions per number of EF-hands is
based on the assumption that the protein complex consists of
equal mols of S100A8 and S100A9. Recently, two reports
have been published by our group revealing that in addition
to the heterodimer, a protein complex with a Mr of 48 kDa is
formed upon calcium binding, consisting of two molecules
S100A8 and two molecules S100A9 [7,24]. Both protein com-
plexes are shown to display AA binding capacity [7]. In con-
trast, Roulin et al. [25] have reported that in human kerati-
nocytes the protein complex is a trimer composed of two
S100A8 and one S100A9 subunit. Therefore, we performed
experiments using di¡erent molar ratios of S100A8 and
S100A9 in the presence of calcium to induce protein complex
formation followed by the determination of AA binding ca-
pacity. The S100A8 and S100A9 proteins were puri¢ed from
human neutrophils and renatured as described in Section 2.
The native proteins were incubated at di¡erent molar ratios in
the presence of 5 mM calcium, and protein-bound AA was
discriminated from the unbound fatty acid using the Lipidex
assay. As shown in Fig. 2, the AA binding capacity of the
formed protein complex was increased at molar ratios of
S100A8 and S100A9 from 1:0.25 to 1:1. Maximal AA binding
Fig. 1. Analysis of calcium ions vs. number of EF-hands within the
protein complex. S100A8/A9 (24 Wg) were incubated with increasing
concentrations of calcium as indicated and 1 WM [3H]AA in a total
volume of 1 ml. The absolute calcium concentrations were measured
by atomic adsorption spectrophotometry. The protein-bound fatty
acids were separated from non-bound fatty acids using the Lipidex
assay. The bars represent data from three independent experiments
with duplicate determinations þ S.D.
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of the protein complex was achieved at a molar ratio of 1 mol
S100A8 and 1 mol S100A9. An increase in the molar ratio of
S100A8 and S100A9 from 1:1 to 1:4 did not enhance AA
binding capacity of the protein complex. These ¢ndings con-
¢rmed the assumption that the protein complex, which is able
to bind AA, consists of equal mols S100A9 and S100A8. This
result is in agreement with other studies [24,26].
3.3. Zinc binding blocked AA binding capacity of S100A8/A9
The C-terminal end of S100A9 contained a His-x-x-x-His
motif followed by an upstream Glu, which may represent the
putative Zn2 binding site. When present in an K-helix, this
motif can bind Zn2 with high a⁄nity, as was found in a
number of naturally occurring proteins [27]. Calcium as well
as zinc binding have been shown to induce conformational
changes within S100 proteins leading to the exposure of hy-
drophobic surfaces [18]. Therefore, we investigated whether
zinc binding also induces the AA binding capacity of the
S100A8/A9 protein complex. The protein complex did not
display AA binding in the range from 1 WM to 1 mM zinc
(data not shown). Then the fatty acid binding assay was per-
formed with S100A8/A9 in the presence of 1 mM calcium and
increasing concentrations of zinc. As shown in Fig. 3C, the
AA binding capacity was reversed by increasing zinc concen-
trations. At 10 WM zinc the protein complex did not display
any AA binding. This value for zinc is within the physiolog-
ical range for serum. Control experiments were performed
with S100A8/A9 and magnesium in the presence and absence
of calcium. The addition of magnesium to S100A8/A9 failed
to induce AA binding capacity (Fig. 3A). However, magnesi-
um did not a¡ect the AA binding capacity of the protein
complex in the presence of calcium indicating that the ob-
served e¡ect was speci¢c for Zn2 (Fig. 3B).
It has been suggested that Zn2 and Cu2 share the same
binding sites [28]. According to this suggestion, we found that
Cu2 failed to induce AA binding capacity of S100A8/A9 and
reversed the AA binding to S100A8/A9 in a concentration-
dependent manner (Fig. 3A,B). The Ki values for zinc and
copper were 5 WM and 2 WM, respectively. The e¡ects of
zinc and copper were additive indicating that copper binds
to the same site as zinc (data not shown).
3.4. Zinc does not in£uence the S100A8/A9 complex formation
It has been demonstrated that the AA binding was speci¢c
for the S100A8/A9 protein complex and the individual com-
ponents were not able to bind AA. Thus, the reversing e¡ect
of Zn2 upon AA binding to S100A8/A9 may be due to zinc-
mediated conformational changes, which prevent protein-pro-
tein interaction. Therefore, an in vitro assay was established
to investigate S100A8-S100A9 interaction in the presence of
zinc. Both S100 proteins were recombinantly expressed each
as histidine- and GST-tagged molecules and used in a GST
pull-down assay in the presence and absence of zinc to mon-
itor the capability of these proteins to associate. As shown in
Fig. 4, zinc ions do not inhibit the protein complex formation
of S100A8 and S100A9. Homodimers were not observed in
Fig. 2. Analysis of the molar ratio of S100A8 and S100A9 in the
protein complex. The puri¢ed and renatured proteins were incu-
bated at di¡erent molar ratios as indicated with 1 WM [3H]AA for
1 h at 37‡C in the presence of 5 mM CaCl2. The protein-bound
fatty acids were separated from non-bound fatty acids using the
Lipidex assay. The bars represent data from three independent ex-
periments with duplicate determinations þ S.D.
Fig. 3. E¡ect of zinc, copper, and magnesium upon AA binding ca-
pacity of S100A8/A9. S100A8/A9 (24 Wg) was incubated with 1 WM
[3H]AA and zinc (100 WM), copper (100 WM), or magnesium (1 mM)
in the absence (A) or presence (B) of 1 mM calcium. C: S100A8/A9
(24 Wg) was incubated with 1 WM [3H]AA in the presence of 1 mM
calcium and increasing concentrations of zinc (b) or copper (F) as
indicated. The protein-bound fatty acids were separated from non-
bound fatty acids using the Lipidex assay. The bars represent data
from three independent experiments with duplicate determina-
tions þ S.D.
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this assay either in the absence or in the presence of zinc. GST
alone bound neither S100A8 nor S100A9.
3.5. Bivalent cations induce conformational changes in
S100A8/A9
Conformational changes within protein molecules after
binding of ligands or after interaction with other proteins
can be monitored by £uorimetric measurements. The £uores-
cence properties of proteins depend mainly on the presence of
aromatic amino acids. There are several aromatic residues
present in each human S100A8 (Trp54, Tyr16, Tyr19, Tyr30,
and Tyr45) and human S100A9 (Trp88 and Tyr22). The Trp
residues have been shown to be sensitive to the residues’ im-
mediate environment and to alter in a characteristic way when
the local environment changes.
The addition of increasing Ca2 concentrations to S100A8/
A9 led to a strong shift of the £uorescence maximum from
342 to about 334 nm and to a decrease in the intensity of the
emission spectrum from 20 000 to about 13 000 cps (Fig.
5A,C). This blue shift is typical for aromatic residues moving
into a more hydrophobic environment. A similar behavior has
been observed for several other S100 proteins (for review see
[2,4]). Here, conformational changes within the homodimer
occur upon Ca2 binding leading to the exposure of hydro-
phobic surfaces. The addition of AA (0.2 WM) did not in£u-
ence these structural changes (Fig. 5A,C).
The addition of Zn2 to S100A8/A9 resulted into di¡erent
conformational changes (Fig. 5B,D). At low Zn2 concentra-
tions both the £uorescence maximum and the £uorescence
intensity were decreased to values comparable to the calci-
um-induced changes. However, at higher Zn2 concentrations
the £uorescence intensity was increased, but not the £uores-
cence maximum. The Zn2-induced changes were not altered
by the simultaneous addition of 10 WM calcium in the pres-
ence of 0.2 WM AA. Surprisingly, the addition of Cu2 to
S100A8/A9 resulted into a signi¢cant decrease in the £uores-
cence intensity, but the £uorescence maximum was not altered
(Fig. 5B,D). In accordance with Zn2, the Cu2-induced
structural changes were not altered by the simultaneous addi-
tion of Ca2 (data not shown). These observations might in-
dicate stronger e¡ects on the protein structure by the binding
of Zn2 and Cu2 than of Ca2. From our data it is suggested
that AA binds to S100A8/A9 when binding of the bivalent
cation induces both a blue shift in the £uorescence maximum
and a decrease in the £uorescence intensity. Therefore, one
can assume that both Zn2 and Cu2 induce structural
changes within the protein complex, which reverses the
Ca2-induced formation of the AA binding site. Furthermore,
we suggest that neither Zn2 nor Cu2 binds to the same
binding site as Ca2, because otherwise the Ca2-induced
changes should be reversed to apo-values. To date the three-
dimensional structure of S100A8/A9 remains unknown. Thus,
one cannot decide whether both Zn2 and Cu2 bind to the
same binding site. However, the di¡erent £uorescence changes
induced by the binding of both bivalent cations may indicate
di¡erent binding sites. The analysis of the three-dimensional
structure of S100A8/A9 is currently under investigation in our
laboratory.
3.6. Ca2+ and Zn2+ binding allow interaction with di¡erent
target proteins and cell surface binding sites
In the past several studies have dealt with the extracellular
role of S100A8 and S100A9. For example, S100A8 and
S100A9 were reported to have growth inhibitory activity
upon cells [29], to have antimicrobial, cytostatic, and chemo-
tactic activities [30^33] as well as stimulating neutrophil adhe-
sion [16]. Recently, we could show that the S100A8/A9 pro-
Fig. 4. S100A8/A9 (MRP8/14) complex formation is not inhibited
by Zn ions. Prior to the addition of glutathione-Sepharose, GST fu-
sion proteins were incubated with His-tagged proteins for 1 h at
4‡C in the presence of 1 mM CaCl2 and increasing concentrations
of ZnCl2 as indicated. The glutathione-Sepharose pellet was washed
followed by the addition of SDS sample bu¡er. Then the suspension
was heated to 100‡C, and the proteins were analyzed by 15% SDS-
PAGE.
Fig. 5. E¡ect of zinc and calcium on Trp and Tyr £uorescence in-
tensity at 342 nm and the £uorescence maximum. Variation of £uo-
rescence intensity at 342 nm (A, B) and £uorescence maximum
(C, D) of S100A8/A9 with increasing concentrations of bivalent cat-
ions in the absence and presence of 0.2 WM arachidonic acid as in-
dicated. Spectra were taken at 20‡C in 20 mM Tris, pH 7.5, 1 mM
DTT at a protein concentration of 0.208 WM. a, S100A8/A9 with
increasing Ca2 concentrations; b, S100A8/A9 with 0.2 WM AA
and increasing Ca2 concentrations; O, S100A8/A9 with 0.2 WM
AA and increasing Zn2 concentrations; R, S100A8/A9 with 0.2 WM
AA, 10 WM Ca2 and increasing Zn2 concentrations; E, S100A8/
A9 with 0.2 WM AA and increasing Cu2 concentrations.
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tein complex is secreted from phorbol myristate acetate-stimu-
lated neutrophil-like HL-60 cells which carry AA, thus assum-
ing a modulatory role in in£ammatory processes, probably as
shuttle protein to transport AA to its target cells [7]. However,
the precise function of S100A8/A9, particularly in the extra-
cellular milieu, remains unclear. The present study represents
the ¢rst report that binding of zinc as well as copper reversed
the property of a S100 protein which has been induced by the
binding of calcium. Both calcium and zinc binding induce
conformational changes within the protein complex, and as
shown in this study, zinc reversed the calcium-induced forma-
tion of an AA binding site. Therefore, it can be envisaged that
di¡erent structural changes are induced by either calcium or
zinc, thus allowing interactions with di¡erent target proteins
as well as di¡erent cell surface binding sites. Thus, the variety
of reported e¡ects for the secreted S100A8/A9 may re£ect that
in some cases the biological activity of S100 proteins is regu-
lated by Zn2 and in other cases by Ca2.
It is likely that secretion of AA-S100A8/A9 complexes takes
place at sites of in£ammation, released by in£ammatory cells
targeted to such loci by a range of environmental cues. Phys-
iological stimuli that induce S100A8/A9 secretion from human
neutrophils are the chemoattractants FMLP and C5a [15] in-
dicating that this mechanism is functional following receptor-
dependent activation of cells. The serum concentration of
Zn2 is within the range 10^20 WM. The basic level of free
intracellular Zn2 is estimated within di¡erent tissue in the
range of 0.024^0.5 nM [34^37]. However, the majority of
Zn2 is bound to proteins. Therefore, the Zn2 concentrations
within cells and tissue are assumed to be below 1 WM indicat-
ing that S100A8/A9 may bind AA in vivo. Consequently, the
AA transport by S100A8/A9 may be limited by the concen-
tration gradient of zinc between the bloodstream and the in-
£ammatory lesion. This may represent another mechanism by
which the property of a secreted protein is restricted to local
environments. Recently, Harrison et al. [38] have demon-
strated that oxidative modi¢cation a¡ects the chemotactic ac-
tivity of murine S100A8. The monomeric and chemotactic
S100A8 are transformed into non-chemotactic S100A8 homo-
dimers by hypochlorite oxidation-driven disul¢de linkage. The
oxidative modi¢cation of murine S100A8 is suggested by the
authors to provide a mechanism limiting excess in¢ltration of
leukocytes and terminating the progression of acute in£am-
mation. However, performing analogous experiments with hy-
pochlorite we could not observe any e¡ect upon the fatty acid
binding capacity of the S100A8/A9 protein complex [7].
Therefore, further investigations should try to identify tar-
get proteins binding to S100 proteins in a Ca2-independent
but Zn2- and Cu2-dependent manner. In addition, they
have to pinpoint the binding sites speci¢c for S100A8 and
S100A9 under consideration of the ion bound to the protein
complex and the cells expressing the putative receptor(s).
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